Further large-scale prospective clinical trial to evaluate the exact role of SGLT2 inhibitors on cervical cancer in real world and the association between SGLT2 inhibitors utilization and the treatment outcome of cervical cancer is mandatory. The gene discussed is SLC5A2; the disease is cervical carcinoma.